Real-World Experience of Fluocinolone Acetonide 0.19 mg in the Management of Non-Infectious Uveitis

References

• Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P, Murray PI. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol. 2004;88(9):1159–1162. doi: 10.1136/bjo.2003.037226.
   PubMed Web of Science ®Google Scholar
• Durrani OM, Meads CA, Murray PI. Uveitis: a potentially blinding disease. Ophthalmologica. 2004;218(4):223–236. doi: 10.1159/000078612.
   PubMed Web of Science ®Google Scholar
• Deschenes J, Murray PI, Rao NA, Nussenblatt RB. International Uveitis Study Group (IUSG): clinical classification of uveitis. Ocul Immunol Inflamm. 2008;16(1):1–2. doi: 10.1080/09273940801899822.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509–516.
   PubMed Web of Science ®Google Scholar
• Rothova A, Schulten Ms S-V, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80(4):332–336. doi: 10.1136/bjo.80.4.332.
   PubMed Web of Science ®Google Scholar
• Mitkova-Hristova VT, Konareva-Kostianeva MI. Macular edema in uveitis. Folia Med (Plovdiv). 2012;54(3):14–21. doi: 10.2478/v10153-011-0092-8.
   PubMedGoogle Scholar
• de Smet MD, Okada AA. Cystoid macular edema in uveitis. Dev Ophthalmol. 2010;47:136–147.
   PubMedGoogle Scholar
• Tan HY, Agarwal A, Lee CS, Chhablani J, Gupta V, Khatri M, et al. Management of noninfectious posterior uveitis with intravitreal drug therapy. Clin Ophthalmol. 2016;10:1983–2020. doi: 10.2147/OPTH.S89341.
   PubMedGoogle Scholar
• Sallam A, Taylor SR, Lightman S. Review and update of intraocular therapy in noninfectious uveitis. Curr Opin Ophthalmol. 2011;22(6):517–522. doi: 10.1097/ICU.0b013e32834bbd68.
   PubMedGoogle Scholar
• Valdes LM, Sobrin L. Uveitis therapy: the corticosteroid options. Drugs. 2020;80(8):765–773. doi: 10.1007/s40265-020-01314-y.
   PubMed Web of Science ®Google Scholar
• Modugno RL, Testi I, Pavesio C. Intraocular therapy in noninfectious uveitis. J Ophthalmic Inflamm Infect. 2021;11(1):37. doi: 10.1186/s12348-021-00267-x.
   PubMed Web of Science ®Google Scholar
• Drugs.com. FDA approves ozurdex for non-infectious uveitis. https://www.drugs.com/newdrugs/allergan-receives-fda-approval-ozurdex-option-non-infectious-uveitis-affecting-posterior-segment-eye-2307.html. 2010
   Google Scholar
• National Institute for Health and Care Excellence. Adalimumab and dexamethasone for treating non-infectious uveitis London https://www.nice.org.uk/guidance/ta460/chapter/1-Recommendations. 2017.
   Google Scholar
• Nawrat A. NICE recommends NHS use of Alimera’s Iluvien for NIPU. Pharmaceutical Technology. https://www.pharmaceutical-technology.com/news/nice-iluvien-nipu/. 2019
   Google Scholar
• EyePoint Pharmaceuticals. EyePoint pharmaceuticals announces sale of YUTIQ® to Alimera Sciences, Inc. For $82.5 Million Cash Plus Royalties EyePoint Pharmaceuticals. https://investors.eyepointpharma.com/news-releases/news-release-details/eyepoint-pharmaceuticals-announces-sale-yutiqr-alimera-sciences. 2023.
   Google Scholar
• London NJ, Chiang A, Haller JA. The dexamethasone drug delivery system: indications and evidence. Adv Ther. 2011;28(5):351–366. doi: 10.1007/s12325-011-0019-z.
   PubMed Web of Science ®Google Scholar
• Kuppermann BD, Zacharias LC, Kenney MC. Steroid differentiation: the safety profile of various steroids on retinal cells in vitro and their implications for clinical use (an American ophthalmological society thesis). Trans Am Ophthalmol Soc. 2014;112:116–141.
   PubMedGoogle Scholar
• Pavesio C, Zierhut M, Bairi K, Comstock TL, Usner DW. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology. 2010;117(3):567–75, 75.e1. doi: 10.1016/j.ophtha.2009.11.027.
   PubMed Web of Science ®Google Scholar
• Zarranz-Ventura J, Carreño E, Johnston RL, Mohammed Q, Ross AH, Barker C, et al. Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: indications, outcomes, and reinjection frequency. Am J Ophthalmol. 2014;158(6):1136–45.e5. doi: 10.1016/j.ajo.2014.09.003.
   PubMed Web of Science ®Google Scholar
• Kim JE, Tomkins-Netzer O, Elman MJ, Lally DR, Goldstein M, Goldenberg D, et al. Evaluation of a self-imaging SD-OCT system designed for remote home monitoring. BMC Ophthalmol. 2022;22(1):261. doi: 10.1186/s12886-022-02458-z.
   PubMed Web of Science ®Google Scholar
• Myung JS, Aaker GD, Kiss S. Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant. Clin Ophthalmol. 2010;4:1423–1426. doi: 10.2147/OPTH.S15696.
   PubMedGoogle Scholar
• Bajwa A, Peck T, Reddy AK, Netland PA, Shildkrot Y. Dexamethasone implantation in birdshot chorioretinopathy - long-term outcome. Int Med Case Rep J. 2018;11:349–358. doi: 10.2147/IMCRJ.S164206.
   PubMed Web of Science ®Google Scholar
• Ajamil-Rodanes S, Testi I, Luis J, Robson AG, Westcott M, Pavesio C. Evaluation of fluocinolone acetonide 0.19 mg intravitreal implant in the management of birdshot retinochoroiditis. Br J Ophthalmol. 2022;106(2):234–240. doi: 10.1136/bjophthalmol-2020-317372.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Foster CS, Pavesio CE, Paggiarino DA, Riedel GE. Effect of an Injectable fluocinolone acetonide insert on recurrence rates in chronic noninfectious uveitis affecting the posterior segment: twelve-month results. Ophthalmology. 2019;126(4):601–610. doi: 10.1016/j.ophtha.2018.10.033.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Pavesio CE. Effect of a fluocinolone acetonide insert on recurrence rates in noninfectious intermediate, posterior, or panuveitis: three-year results. Ophthalmology. 2020;127(10):1395–1404. doi: 10.1016/j.ophtha.2020.04.001.
   PubMed Web of Science ®Google Scholar
• Weber LF, Marx S, Auffarth GU, Scheuerle AF, Tandogan T, Mayer C, et al. Injectable 0.19-mg fluocinolone acetonide intravitreal implant for the treatment of non-infectious uveitic macular edema. J Ophthalmic Inflamm Infect. 2019;9(1):3. doi: 10.1186/s12348-019-0168-9.
   PubMedGoogle Scholar
• Moreno-Castro L, García-García GP, Artaraz J, Fonollosa A. Fluocinolone implant for idiopathic retinal vasculitis, aneurysms, and neuroretinitis syndrome: a case report. Case Rep Ophthalmol. 2021;12(3):824–830. doi: 10.1159/000518011.
   PubMed Web of Science ®Google Scholar
• Schiffman RM, Jacobsen G, Whitcup SM. Visual functioning and general health status in patients with uveitis. Arch Ophthalmol. 2001;119(6):841–849. doi: 10.1001/archopht.119.6.841.
   PubMed Web of Science ®Google Scholar
• Balasubramaniam B, Chong YJ, Azzopardi M, Logeswaran A, Denniston AK. Topical anti-inflammatory agents for non-infectious uveitis: current treatment and perspectives. J Inflamm Res. 2022;15:6439–6451. doi: 10.2147/JIR.S288294.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Callanan D, Dugel P, Godfrey DG, Goldstein DA, Wilensky JT. Treating chronic noninfectious posterior segment uveitis: the impact of cumulative damage. Proceedings of an expert panel roundtable discussion. Retina. 2006;26(8):1–16. doi:10.1097/01.iae.0000250601.15893.5f.
   Google Scholar